CB-001

N/A

Report date: 2023/02/17 21:03:15

Base Information

Drug NameCB-001
Drug Alias NameCB-001
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesLymphoma, Non-HodgkinLeukemia, Myeloid, Acute +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesViacell
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesViacell
Active IndicationsN/A
Inactive IndicationsMyelodysplastic SyndromesLymphoma, Non-HodgkinLeukemia, Myeloid, Acute +[5] 

Other Information

ATC CodeN/A
Related LinksN/A